You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

174 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Apr 2020
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Keytruda®
Jun 2025
Drug
Other Name(s): Iclusig®
Aug 2023
Drug
Other Name(s): Vectibix®
Jan 2025
Drug
Other Name(s): Perjeta®
Sep 2022
Drug
Feb 2024
Drug
Other Name(s): Votrient®
Dec 2024
Drug
Other Name(s): Caelyx®
Mar 2025
Drug
Other Name(s): Pomalyst®
Apr 2025
Drug
Other Name(s): Taxol®
Nov 2024
Drug
Other Name(s): Alimta®
Apr 2023

Pages